Curanex flags going-concern risk with $1.58M cash
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Curanex Pharmaceuticals Inc (CURX) reported a net loss of $9,256,795 for the nine months ended September 30, 2026, compared with $1,151,988 a year earlier, and generated no revenue in either period. Research and development expense was $6,802,466. Cash used in operating activities was $3,393,445, while cash and cash equivalents were $1,579,689 at September 30; prepaid R&D balances funded part of expenses.
The company said its existing cash is not expected to fund operations for at least 12 months from issuance of the statements, raising substantial doubt about its ability to continue as a going concern. It plans to seek financing, collaborations or out-licensing and may reduce or defer discretionary spending, but said these plans do not alleviate the doubt. Curanex is targeting an ulcerative-colitis IND submission in the fourth quarter of 2026, which may occur in 2027, depending partly on FDA feedback and completion of studies. A GMP pilot-scale batch of Phyto-N was completed, and GLP toxicology and pharmacokinetic studies are underway. Management concluded disclosure controls and procedures were ineffective as of September 30.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- None.
Negative
- Major pointNine-month net loss: $9,256,795, versus $1,151,988 in 2025.
- Major pointGoing-concern warning: $1,579,689 cash at September 30, 2026.
Filing Explained
The consultant share awards brought no cash proceeds to fund operations.
This report says Curanex Pharmaceuticals had issued 150,000 shares to six consultants under its 2026 Plan by
The 2026 Plan reserves 285,000 shares in total, and plan awards are settled in common shares. Separately, the 1-for-20 reverse split took effect on
The two putative securities class actions related to the August 2025 IPO were at a preliminary stage, sought unspecified relief, and had response deadlines of
Key Figures
Key Terms
substantial doubt financial
going concern financial
Investigational New Drug medical
pre-IND meeting request regulatory
Good Laboratory Practice medical
chemistry, manufacturing, and controls technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What was CURX's net loss for the first nine months of 2026?
When does CURX expect to submit its ulcerative-colitis IND?
Why was CURX's operating cash use lower than its net loss?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
(Mark One)
For
the quarterly period ended
Commission
File No.
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of | (I.R.S. Employer | |
| incorporation or organization) | Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
(Registrant’s telephone number, including area code)
N/A
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of exchange on which registered | ||
| The |
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| ☐ | Large accelerated filer | ☐ | Accelerated filer |
| ☒ | Smaller reporting company | ||
| Emerging growth company |
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No
As
of November 13, 2026, the registrant had
TABLE OF CONTENTS
| Page | ||
| PART I – FINANCIAL INFORMATION | 4 | |
| Item 1. | Unaudited Financial Statements. | 4 |
| Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations. | 21 |
| Item 3. | Quantitative and Qualitative Disclosures about Market Risk. | 26 |
| Item 4. | Controls and Procedures. | 26 |
| PART II – OTHER INFORMATION | 27 | |
| Item 1. | Legal Proceedings. | 27 |
| Item 1A. | Risk Factors. | 27 |
| Item 2. | Unregistered Sales of Equity Securities. | 27 |
| Item 3. | Defaults Upon Senior Securities. | 27 |
| Item 4. | Mine Safety Disclosures. | 27 |
| Item 5. | Other Information. | 27 |
| Item 6. | Exhibits. | 27 |
| SIGNATURES | 28 | |
| 2 |
FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q (the “Quarterly Report”) contains forward-looking statements that reflect management’s current views with respect to future events and financial performance. Forward-looking statements are projections in respect of future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. Forward-looking statements contained in the Quarterly Report include, but are not limited to, statements about:
| ● | our future financial performance, including our revenue, costs of revenue, operating expenses and profitability; | |
| ● | our ability to meet our liquidity needs and to raise additional capital on acceptable terms, if needed; | |
| ● | the availability of financing for smaller publicly traded companies like us; and | |
| ● | our ability to effectively manage our growth and future expenses. |
We cannot predict all of the risks and uncertainties. Accordingly, such information should not be regarded as representations that the results or conditions described in such statements or that our objectives and plans will be achieved and we do not assume any responsibility for the accuracy or completeness of any of these forward-looking statements. These forward-looking statements include information concerning possible or assumed future results of our operations, including statements about our business strategies; future cash flows; financing plans; plans and objectives of management; any other statements regarding future acquisitions, future cash needs, future operations, business plans and future financial results, our ability to obtain or maintain patents or other appropriate protection for our intellectual property, and any other statements that are not historical facts.
These statements are only predictions and involve known and unknown risks, uncertainties and other factors. Readers are urged to carefully review and consider the various disclosures made by us in this Quarterly Report and in our other reports filed with the Securities and Exchange Commission (the “SEC”). Except to the extent required by law, we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, a change in events, conditions, circumstances or assumptions underlying such statements, or otherwise.
As used in this Quarterly Report and unless otherwise indicated, the terms “Curanex,” “we,” “us,” “our,” or “Company” refer to Curanex Pharmaceuticals Inc, a Nevada corporation.
On August 20, 2026, the Company effected a 1-for-20 reverse stock split of its outstanding shares of common stock (the “Reverse Stock Split”). Unless specified otherwise, and except as provided in the financial statements and footnotes thereto, all references in this Quarterly Report to share and per share data have been adjusted, including historical data which has been retroactively adjusted, to give effect to the Reverse Stock Split.
| 3 |
CURANEX PHARMACEUTICALS INC
AS OF SEPTEMBER 30, 2026
PART I- FINANCIAL INFORMATION
Item 1. Financial Statements.
INDEX TO FINANCIAL STATEMENTS
| Balance Sheets | 5 |
| Statements of Operations | 6 |
| Statements of Changes in Shareholders’ Equity | 7 |
| Statements of Cash Flows | 8 |
| Notes to Financial Statements | 9 |
| 4 |
CURANEX PHARMACEUTICALS INC
BALANCE SHEETS
As of September 30, 2026 | As of December 31, 2025 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash | $ | $ | ||||||
| Prepaid Expenses | ||||||||
| Total current assets | ||||||||
| Right-of-Use Asset | ||||||||
| TOTAL ASSETS | $ | $ | ||||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||
| Current liabilities | ||||||||
| Accrued expenses | $ | $ | ||||||
| Accounts payable | - | |||||||
| Lease Liability, current | ||||||||
| Total current liabilities | ||||||||
| Lease Liability, noncurrent | ||||||||
| TOTAL LIABILITIES | ||||||||
| Shareholders’ equity | ||||||||
| Common stock, | ||||||||
| Preferred stock, | ||||||||
| Additional paid-in capital | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| TOTAL SHAREHOLDERS’ EQUITY | ||||||||
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $ | $ | ||||||
| [1] |
The accompanying notes are an integral part of these unaudited financial statements.
| 5 |
CURANEX PHARMACEUTICALS INC
UNAUDITED STATEMENTS OF OPERATIONS
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| For the Three Months Ended | For the Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Operating expenses: | ||||||||||||||||
| General & administrative | $ | $ | $ | $ | ||||||||||||
| Research & Development | ||||||||||||||||
| Total operating expenses | ||||||||||||||||
| Loss from operations | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Interest Expense | - | ( | ) | - | ( | ) | ||||||||||
| Other income | ||||||||||||||||
| Net Loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Net loss per common share: Basic and Diluted | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Weighted average number of common shares outstanding: Basic and Diluted[1] | ||||||||||||||||
| [1] |
The accompanying notes are an integral part of these unaudited financial statements.
| 6 |
CURANEX PHARMACEUTICALS INC
UNAUDITED STATEMENT OF CHANGES IN SHAREHOLDERS’ EQUITY
| Number of Shares [1] | Amount | Number of Shares | Amount | Stock to be Issued | Paid-in Capital | Accumulated Deficit | Total | |||||||||||||||||||||||||
| Common Stock | Preferred Stock | Common | Additional | |||||||||||||||||||||||||||||
| Number of Shares [1] | Amount | Number of Shares | Amount | Stock to be Issued | Paid-in Capital | Accumulated Deficit | Total | |||||||||||||||||||||||||
| Balance at December 31, 2024 | $ | $ | $ | $ | $ | ( | ) | $ | ||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||
| Balance at March 31, 2025 | $ | $ | $ | $ | $ | ( | ) | $ | ||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||
| Balance at June 30, 2025 | $ | $ | $ | $ | $ | ( | ) | $ | ||||||||||||||||||||||||
| Issuance of common stocks | - | - | ( | ) | - | |||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||
| Balance at September 30, 2025 | $ | $ | $ | - | $ | $ | ( | ) | $ | |||||||||||||||||||||||
| Balance at December 31, 2025 | $ | $ | $ | - | $ | $ | ( | ) | $ | |||||||||||||||||||||||
| Share based compensation | - | - | - | - | - | |||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||
| Balance at March 31, 2026 | $ | $ | $ | - | $ | $ | ( | ) | $ | |||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||
| Balance at June 30, 2026 | $ | $ | $ | - | $ | $ | ( | ) | $ | |||||||||||||||||||||||
| Shares issued for consulting services | - | - | - | - | ||||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||
| Balance at September 30, 2026 | $ | $ | $ | - | $ | $ | ( | ) | $ | |||||||||||||||||||||||
| [1] |
The accompanying notes are an integral part of these unaudited financial statements.
| 7 |
CURANEX PHARMACEUTICALS INC.
STATEMENTS OF CASH FLOWS
(unaudited)
| 2026 | 2025 | |||||||
| For the Nine Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net loss for the period | $ | ( | ) | $ | ( | ) | ||
| Adjustments to reconcile net income to net cash provided by (used in) operating activities: | ||||||||
| Amortization of right-of-use assets | ||||||||
| Stock-based Compensation Expense | - | |||||||
| Changes in operating assets and liabilities: | ||||||||
| Prepaid expenses | ( | ) | ||||||
| Lease liabilities | ( | ) | ( | ) | ||||
| Accounts payable | ( | ) | ||||||
| Interest payable | - | - | ||||||
| Accrued expenses | ( | ) | ||||||
| NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES | ( | ) | ( | ) | ||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Proceeds from issuance of common stock, net of underwriting costs | - | |||||||
| Payment of offering costs | - | ( | ) | |||||
| NET CASH PROVIDED BY FINANCING ACTIVITIES | - | |||||||
| NET INCREASE (DECREASE) IN CASH | ( | ) | ||||||
| Cash at beginning of period | ||||||||
| CASH AT END OF PERIOD | $ | $ | ||||||
| Supplemental schedule of cash flow information: | ||||||||
| Recognition of right-of-use asset in exchange for lease liability | $ | $ | ||||||
The accompanying notes are an integral part of these unaudited financial statements.
| 8 |
CURANEX PHARMACEUTICALS INC
NOTES TO FINANCIAL STATEMENTS
1. Description of Business and Summary of Significant Accounting Policies
Description of Business
Curanex Pharmaceuticals Inc (the “Company”) was originally incorporated as Durand Damiel Health Inc. under the laws of the State of New York on June 1, 2018. The Company is headquartered in Jericho, NY, with an initial focus on research and development of health products and botanical medicines.
On November 9, 2023, the Company was rebranded as Curanex Pharmaceuticals Inc, and shifted its focus to discovering, developing, and commercializing innovative botanical drugs for treating major unmet medical needs in patients with inflammatory diseases.
On June 10, 2024, Curanex Pharmaceuticals Inc., a New York corporation (“Curanex NY”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Curanex Pharmaceuticals Inc, (the “Surviving Corporation”), a newly formed Nevada corporation and wholly owned subsidiary of Curanex NY. Pursuant to the Merger Agreement, on the same date, Curanex NY, as the parent in this transaction, merged with and into the Surviving Corporation (the “Reincorporation Merger”). Upon the consummation of the Reincorporation Merger, Curanex NY ceased its legal existence as a New York corporation, and the Surviving Corporation continued the business as the surviving corporation under the name “Curanex Pharmaceuticals Inc”.
The financial statements for the year ended 2024 reflect the impact of the Reincorporation Merger. In accordance with ASC 805 Business Combinations, the merger has been treated as a reorganization under common control. As such, the assets and liabilities have been transferred to the Surviving Corporation at their historical carrying amounts, and no gain or loss has been recognized in connection with the merger. The balance sheet now presents the Nevada corporation as the surviving entity, incorporating the combined assets and liabilities of the predecessor and the successor entities.
This merger did not result in any changes to the reported financial position or results of operations for prior periods, as the historical financial information of the Company has been carried forward to the Surviving Corporation. The impact of the merger on the financial statements is primarily legal and administrative, ensuring the continuity of the Company’s operations under the new jurisdiction without interruption. Consequently, the financial statements include all transactions and balances of both the original and the surviving entities, presented as if the merger had occurred at the beginning of the earliest period presented. This approach ensures consistency and comparability in the financial reporting of the Company’s ongoing business activities.
On August 27, 2025, the Company successfully completed its initial public offering (the “IPO”) and began trading on the Nasdaq Capital Market under the ticker symbol “CURX.”
Following
the completion of our IPO, the Company incurred significant research and development (“R&D”) expense, totaling approximately
$
| 9 |
During 2026, the Company expanded its drug development pipeline by adding oncology as a new core therapeutic area, supplementing its existing six core therapeutic areas. Patients with advanced or relapsed cancers often have limited treatment alternatives, representing substantial unmet medical needs and considerable long-term commercial potential. While continuing to advance its lead preclinical candidate Phyto-N and other pipeline assets targeting inflammatory and metabolic diseases, the Company’s strategic expansion into oncology further diversifies its product portfolio, aligns with its long-term therapeutic development focus, and strengthens its overall positioning as an emerging biotechnology company.
On
July 22, 2026, the Board approved, by unanimous written consent,
Basis of Accounting
The accompanying financial statements of the Company have been prepared on the accrual basis of accounting in accordance with Generally Accepted Accounting Principles in the United States of America (GAAP).
Use of Estimates
The preparation of the Company’s unaudited interim financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions reflected in these interim financial statements are consistent with those described in the Company’s most recent annual financial statements.
These estimates and assumptions are based on historical experience and other factors that management believes are reasonable under the circumstances. Due to the inherent uncertainty involved in making estimates, actual results could differ from those estimates, and such differences may be material to the financial statements.
Management evaluates its estimates on an ongoing basis. Changes in estimates are recognized in the period in which they become known and, if applicable, in future periods.
Going Concern
At the end of each reporting period, management exercises judgment in assessing the Company’s ability to continue as a going concern in accordance with ASC 205-40, Presentation of Financial Statements—Going Concern, by reviewing the Company’s performance, resources, and future obligations. This assessment considers conditions and events that are known and reasonably knowable as of the date the financial statements are issued and involves critical judgments regarding the Company’s short and long-term operating budgets, expected profitability, investment and financing activities, and strategic planning.
The
Company did not generate operating revenue during the recent several years and has incurred recurring net losses and negative cash flows
from operations. For the nine months ended September 30, 2026, the Company incurred a net loss of $
The
Company’s operating expenses for the nine months ended September 30, 2026 were partially funded through the utilization of prepaid
research and development balances, which declined from $
| 10 |
Based on its current operating plan, the Company does not expect its existing cash and cash equivalents to be sufficient to fund operations for at least twelve months from the date these unaudited interim financial statements are issued. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans to address these conditions include raising additional capital through the issuance of equity or debt securities, pursuing strategic collaborations or out-licensing arrangements for its product candidates, and reducing or deferring discretionary operating and development expenditures. There can be no assurance that the Company will be able to obtain additional financing on acceptable terms, or at all. The Company regained compliance with the Nasdaq minimum bid price requirement on September 3, 2026; its ability to obtain additional financing remains uncertain. Because these plans are not considered probable of being effectively implemented within the meaning of ASC 205-40, they do not alleviate the substantial doubt.
The accompanying unaudited interim financial statements have been prepared assuming the Company will continue as a going concern and do not include any adjustments to the carrying amounts or classification of assets and liabilities that might result from the outcome of this uncertainty.
Cash
The
Company maintains balances with multiple financial institutions, with balances periodically exceeding the Federal Deposit Insurance Corporation
(FDIC) insurance limit of $
Basic and Diluted Net Loss per Common Share
The Company computes loss per share in accordance with ASC 260, Earnings per Share, which requires presentation of both basic and diluted earnings per share on the face of the statement of operations. Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of outstanding common shares during the period. Diluted loss per share gives effect to all dilutive potential common shares outstanding during the period. During the nine months ended September 30, 2026, and 2025, the Company had no potential dilutive instruments and accordingly basic loss and diluted loss per share are the same.
Initial Public Offering
The
Company completed its IPO of
In
connection with the IPO, total offering costs were approximately $
| 11 |
Over-Allotment Option
On
September 12, 2025, the underwriters exercised their option to purchase an additional
Fair Value of Financial Instruments
ASC 820 Fair Value Measurements and Disclosures establishes a framework for all fair value measurements and expands disclosures related to fair value measurement and developments. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.
ASC 820 requires that assets and liabilities measured at fair value are classified and disclosed in one of the following three categories:
| ● | Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities; | |
| ● | Level 2 – Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly; and | |
| ● | Level 3 – Inputs that are not based on observable market data. |
The carrying amounts of cash and accrued liabilities approximate fair value because of the short-term nature of these items.
Leases & Right of Use Assets
The Company adopted ASC 842 Leases on January 1, 2022. At inception of a contract, the Company assesses whether a contract is, or contains, a lease. Contracts that convey the right to control the use of an identified asset for a period of time in exchange for consideration are accounted for as leases giving rise to right-of-use assets. At the commencement date, a right-of-use asset is measured at cost, where cost comprises: (a) the amount of the initial measurement of the lease liability; (b) any lease payments made at or before the commencement date, less any lease incentives received; (c) any initial direct costs incurred by the Company; and (d) an estimate of costs to be incurred by the Company in dismantling and removing the underlying asset, restoring the site on which it is located or restoring the underlying asset to the condition required by the terms and conditions of the lease, unless those costs are incurred to produce inventories.
A lease liability is initially measured at the present value of the unpaid lease payments. Subsequently, the Company measures a lease liability by: (a) increasing the carrying amount to reflect interest on the lease liability; (b) reducing the carrying amount to reflect the lease payments made; and (c) re-measuring the carrying amount to reflect any reassessment or lease modifications, or to reflect revised in-substance fixed lease payments. Each lease payment is allocated between repayment of the lease principal and interest. Interest on the lease liability in each period during the lease term is allocated to produce a constant periodic rate of interest on the remaining balance of the lease liability. Except where the costs are included in the carrying amount of another asset, the Company recognizes in profit or loss (a) the interest on a lease liability and (b) variable lease payments not included in the measurement of a lease liability in the period in which the event or condition that triggers those payments occurs. The Company subsequently measures a right-of-use asset at cost less any accumulated amortization and any accumulated impairment losses; and adjusted for any re-measurement of the lease liability. Right-of-use assets are depreciated over the shorter of the asset’s useful life and the lease term.
Research and Development Costs
The Company accounts for research and development (“R&D”) costs in accordance with ASC 730, Research and Development. R&D costs are expensed as incurred unless they represent nonrefundable advance payments for goods or services to be received in the future. Nonrefundable advance payments to third parties—such as Contract Research Organizations (“CROs”), Contract Development and Manufacturing Organizations (“CDMOs”), clinical sites, and other service providers—are recorded as prepaid expenses and recognized in R&D expense as the related services are performed, generally over the contractual period of performance.
| 12 |
R&D expense primarily includes employee-related costs (salaries, benefits, and stock-based compensation) for personnel engaged in R&D; fees to CROs, CDMOs, consultants, and other third parties; clinical trial and preclinical study costs; and costs to manufacture and test preclinical and clinical materials. The Company records accruals for services performed but not yet invoiced based on estimates of work completed, patient enrollment/visits, manufacturing progress, and data from vendors. Up-front set-up or activation fees under executory service arrangements are deferred and recognized over the expected period of performance. Materials, equipment, and licenses with no alternative future use are expensed when incurred; items with alternative future use are capitalized and recognized in accordance with the applicable guidance. Prepaid R&D balances are evaluated for recoverability and adjusted for changes in project scope, timing, or cancellations.
Stock-Based Compensation
The Company accounts for stock-based compensation in accordance with ASC 718, Compensation—Stock Compensation. Share-based payment awards granted to employees, non-employee directors and non-employee service providers are measured at the grant-date fair value of the award and recognized as compensation expense over the requisite service period, which is generally the vesting period. Employee awards that are fully vested on the grant date are expensed in full at that date. For nonemployee awards, the corresponding cost is recognized as an immediate expense or a prepaid asset based on the goods or services acquired and the enforceable rights conveyed by the arrangement. The fair value of awards of common stock and restricted stock is determined by reference to the closing price of the Company’s common stock as reported on Nasdaq on the grant date. The fair value of stock options, if granted, is estimated using the Black-Scholes option-pricing model, which requires management to make assumptions regarding the expected term, expected volatility, risk-free interest rate and expected dividend yield. Because the Company has limited trading history, expected volatility is estimated by reference to the historical volatility of a group of comparable publicly traded companies. The Company has elected to account for forfeitures as they occur. Stock-based compensation expense is classified within research and development expense or general and administrative expense based on the function of the recipient’s services.
For fully vested nonemployee consulting shares issued during the third quarter of 2026 in exchange for enforceable rights to future services, the Company recognizes prepaid services at grant-date fair value and recognizes the related expense as services are received over the contractual service periods. Immediate vesting of the shares does not accelerate recognition of services not yet received.
Income Taxes
The Company accounts for income taxes under ASC 740, Income Taxes. This standard requires the Company to use the asset and liability method, which involves making estimates and assumptions and exercising judgment regarding the carrying values of assets and liabilities. These values are subject to inherent accounting estimates, the interpretation of income tax legislation across various jurisdictions, expectations about future operating results, the timing of reversal of temporary differences, and potential audits of income tax filings by tax authorities. Deferred tax assets and liabilities are recognized for the future tax consequences of differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. These assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years when those temporary differences are expected to be recovered or settled. The impact of changes in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. Valuation allowances are established when necessary to reduce deferred tax assets to amounts expected to be realized.
When the Company incurs losses for income tax purposes, it assesses the probability of future taxable income based on budgeted forecasts. These forecasts are adjusted to account for non-taxable income and expenses and specific rules on the use of unused credits and tax losses. If the forecasts indicate that sufficient future taxable income will not be available to deduct the temporary differences, a deferred tax asset is not recognized for all deductible temporary differences.
Related Party Transactions
The Company identifies and accounts for related party transactions, disclosing them in accordance with ASC 850, Related Party Disclosures, and other relevant ASC standards. Parties are considered related to the Company if they, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include the principal owners of the Company, its management, members of the immediate families of the principal owners and management, and other parties with which the Company may engage in transactions if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.
| 13 |
Segment Reporting
Operating
segments are defined as components of an entity where discrete financial information is evaluated regularly by the chief operating decision
maker (“CODM”) in deciding how to allocate resources and in assessing performance. The Company’s Chief Executive Officer
is its CODM. The Company’s CODM uses GAAP financial statements for the purposes of making operating decisions, allocating resources
and evaluating financial performance. As such, the Company has determined that it operates in
Recent Accounting Pronouncements
The Company is classified as an “emerging growth company” (EGC) under the Jumpstart Our Business Startups Act of 2012 (the JOBS Act). This classification allows EGCs to delay adopting new or revised accounting standards issued after the enactment of the JOBS Act until these standards apply to private companies. The Company has chosen to delay the adoption of these new or revised accounting standards.
The Company is classified as a “smaller reporting company” (SRC) under the Securities and Exchange Commission (SEC) regulations. This classification allows SRCs to provide scaled disclosures in their SEC filings, including reduced financial statement and executive compensation disclosure requirements. The Company has elected to take advantage of these scaled disclosure requirements to simplify its reporting processes.
The Company evaluated the impact of ASU 2024-03, Disaggregation of Income Statement Expenses, issued by the Financial Accounting Standards Board (“FASB”) in November 2024. The update requires additional disclosures to provide disaggregated information about certain expense captions presented in the income statement, including, among other items, inventory, employee compensation, depreciation, and amortization, to enhance transparency into the nature of expenses. The amendments in ASU 2024-03 are effective for annual reporting periods beginning after December 15, 2026, and interim periods thereafter, with early adoption permitted. The Company is currently evaluating the impact that the adoption of this standard will have on its financial statement disclosures. While the standard is not expected to have an impact on the Company’s results of operations, financial position, or cash flows, it is expected to result in expanded disclosures upon adoption.
In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-09, Improvements to Income Tax Disclosures (Topic 740). The ASU requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as additional information on income taxes paid. The Company adopted this ASU on a prospective basis effective January 1, 2025. Refer to Note 5, Income Taxes for the inclusion of new disclosures required.
In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements. The amendments consolidate interim disclosure requirements and clarify the information to be provided about material developments since the last annual reporting period. They are effective for interim periods within annual periods beginning after December 15, 2027 for public business entities and after December 15, 2028 for other entities, with early adoption permitted. The Company is evaluating the disclosure effects and the application of its emerging growth company extended-transition election.
Apart from as mentioned above, management does not believe that other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the Company’s balance sheets, statements of operations, or cash flows.
| 14 |
2. Accrued Expenses
A summary of accrued expenses is as follows:
Schedule of Accrued Expenses
| As of September 30, 2026 | As of December 31, 2025 | |||||||
| Accounting fees | $ | - | $ | |||||
| Payroll expenses | ||||||||
| Rent | - | |||||||
| Tax fees | - | |||||||
| Total Accrued Expenses | $ | $ | ||||||
3. Prepaid expenses
A summary of prepaid expenses is as follows:
Schedule of Prepaid Expenses
| As of September 30, 2026 | As of December 31, 2025 | |||||||
| Insurance | $ | $ | ||||||
| R&D | ||||||||
| Other | ||||||||
| Total Prepaid Expenses | $ | $ | ||||||
4. Lease
On
January 1, 2025, the Company assumed an office lease from Duraviva Pharma Inc. (“Duraviva”), a New York corporation under
common control, through a lease assignment agreement.
During
the fourth quarter of 2025, the Company entered into lease agreements for three motor vehicles with non-cancelable lease terms ranging
from
The following summarizes information about the Company’s lease as of September 30, 2026 and December 31, 2025.
Schedule of Lease
| 2026 | 2025 | |||||||
For the Three Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| Amount recognized in the income statements | ||||||||
| Operating lease expense | $ | $ | ||||||
| 2026 | 2025 | |||||||
For the Nine Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| Amount recognized in the income statements | ||||||||
| Operating lease expense | $ | $ | ||||||
| 15 |
| As of September 30, 2026 | As of December 31, 2025 | |||||||
| Amount recognized in the balance sheets | ||||||||
| Right-of-use assets | $ | $ | ||||||
| Operating lease liabilities | ||||||||
| Amount recognized in the income statements | ||||||||
| Cash paid for amounts included in the measurement of lease liabilities | ||||||||
| Operating lease expense | $ | $ | ||||||
| Lease commitment | ||||||||
| 2026 | $ | $ | ||||||
| 2027 | ||||||||
| 2028 | ||||||||
| 2029 | ||||||||
| 2030 | - | |||||||
| Thereafter (2031) | - | |||||||
| Total future minimum lease payments | ||||||||
| less imputed interest | ( | ) | ( | ) | ||||
| Present value of lease liabilities | $ | $ | ||||||
| Supplement information | ||||||||
| Discount rate | % | % | ||||||
| Remaining lease term | ||||||||
5. Income Taxes
Due to the Company’s net losses and the valuation allowance provided on the related deferred tax assets, there were no provisions for income taxes for the nine months ended September 30, 2026 and 2025.
The components of income tax provision (benefit) for the nine months ended September 30, 2026 and 2025 are as follows:
Schedule of Components of Income Tax Provision (benefit)
| 2026 | 2025 | |||||||
For the Three Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| Current income tax expense: | ||||||||
| Federal | $ | - | $ | - | ||||
| State and local | - | - | ||||||
| Total current income tax expense: | - | - | ||||||
| Deferred income tax expense (benefit) | ||||||||
| Federal | - | - | ||||||
| State and local | - | - | ||||||
| Total deferred income tax expense | - | - | ||||||
| Total income tax provision (benefit) | $ | - | $ | - | ||||
| 16 |
| 2026 | 2025 | |||||||
For the nine Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| (Unaudited) | (Unaudited) | |||||||
| Current income tax expense: | ||||||||
| Federal | $ | - | $ | - | ||||
| State and local | - | - | ||||||
| Total current income tax expense: | - | - | ||||||
| Deferred income tax expense (benefit) | ||||||||
| Federal | - | - | ||||||
| State and local | - | - | ||||||
| Total deferred income tax expense | - | - | ||||||
| Total income tax provision (benefit) | $ | - | $ | - | ||||
The following table presents a reconciliation of the U.S. federal statutory income tax rate to the Company’s effective tax rate for the nine months ended September 30, 2026 and 2025:
Schedule of Reconciliation of Effective Tax Rate
Three Months Ended September 30, 2026 | Three Months Ended September 30, 2025 | |||||||||||||||
| (Unaudited) | (Unaudited) | |||||||||||||||
| Amount | Percent | Amount | Percent | |||||||||||||
| U.S. federal statutory tax rate | $ | ( | ) | % | $ | ( | ) | % | ||||||||
| State and local income taxes, net of federal effect | — | — | % | — | — | % | ||||||||||
| Nontaxable or nondeductible items | — | — | % | — | — | % | ||||||||||
| Changes in valuation allowance | - | % | - | % | ||||||||||||
| Income tax expense and effective tax rate | $ | — | — | % | $ | — | — | % | ||||||||
Nine Months Ended September 30, 2026 | Nine Months Ended September 30, 2025 | |||||||||||||||
| (Unaudited) | (Unaudited) | |||||||||||||||
| Amount | Percent | Amount | Percent | |||||||||||||
| U.S. federal statutory tax rate | $ | ( | ) | % | $ | ( | ) | % | ||||||||
| State and local income taxes, net of federal effect | — | — | % | — | — | % | ||||||||||
| Nontaxable or nondeductible items | — | — | % | — | — | % | ||||||||||
| Changes in valuation allowance | - | % | - | % | ||||||||||||
| Income tax expense and effective tax rate | $ | — | — | % | $ | — | — | % | ||||||||
Deferred income tax assets as of September 30, 2026 and December 31, 2025, are as follows:
Schedule of Deferred Income Tax Assets
As of September 30, 2026 | As of December 31, 2025 | |||||||
| Net operating losses carry forwards | $ | $ | ||||||
| Others | - | |||||||
| Total deferred tax assets | ||||||||
| Less valuation allowance | ( | ) | ( | ) | ||||
| Total deferred tax assets | $ | - | $ | - | ||||
In assessing the realization of deferred tax assets, management evaluates whether it is more likely than not that some or all of these assets will not be realized. The ultimate realization of deferred tax assets depends on generating future taxable income during the periods when these temporary differences become deductible.
Based
on the available objective evidence, management believes it is more likely than not that the net deferred tax assets will not be realizable.
Accordingly, the Company has applied a full valuation allowance against its net deferred tax assets as of September 30, 2026 and December
31, 2025. The net change in the total valuation allowance between December 31, 2025, and September 30, 2026, was an increase of $
| 17 |
The Company is subject to U.S. federal and state income tax examinations by the Internal Revenue Service (IRS) and relevant state tax authorities. The Company is incorporated in the state of Nevada, which does not impose a corporate income tax.
The
Company’s policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.
As of September 30, 2026, and December 31, 2025, the Company did not have any significant uncertain tax positions or unrecognized tax
benefits. Additionally, as of September 30, 2026, and December 31, 2025, the Company has federal net operating loss carryforwards of
$
6. Related Party Transactions
In January 2025, Duraviva also assigned its office lease to the Company. The terms of the lease, including the original lease end date, remained unchanged upon reassignment. The Company accounted for the lease under ASC 842 as an operating lease. Please refer to Note 4 Lease.
In
February and May 2025, the Company received two $
In
September 2025, following the completion of the Company’s IPO, the shareholder loans were fully repaid, including all accrued interest.
Total interest paid upon settlement amounted to $
7. Shareholders’ Equity
Common Stock
The
Company is authorized to issue
As
of December 31, 2024, the Company had
During the year of 2025, the Company completed the following equity issuances in connection with its initial public offering and related activities:
| ● | ||
| ● | ||
| ● |
Following
these issuances, the Company had
On
March 18, 2026, the Company issued an aggregate of
| 18 |
Subscriptions Received – Shares to be Issued
In
2019, the Company received $
Following
the successful completion of the IPO, the Company issued
Preferred Stock
The
Company is authorized to issue
8. Stock-Based Compensation
2026 Equity Incentive Plan
On
May 31, 2026, the Company’s Board of Directors adopted the Curanex Pharmaceuticals Inc 2026 Equity Incentive Plan (the “2026
Plan”), which was approved by the Company’s stockholders on June 11, 2026. The 2026 Plan permits the grant of stock options,
restricted stock, restricted stock units and other stock-based awards to employees, directors and consultants of the Company. An aggregate
of
On
July 21, 2026, the Company filed a Registration Statement on Form S-8 with the Securities and Exchange Commission registering
During
the third quarter of 2026, the Company granted and issued
The
grant-date fair value of these awards was $
| 19 |
The
Company recognized consulting expense of $
Other Stock-Based Compensation
On
March 18, 2026, the Company issued an aggregate of
9. Commitments and Contingencies
The following two (2) putative securities class actions were commenced in New York state court relating to the Company’s August 2025 IPO:
The first action (“Action 1”) was filed on July 23, 2026 in the Supreme Court of the State of New York, New York County (Index No. 159271/2026), by Daymond Morales, et al. against the Company and its underwriters Dominari Securities LLC, Pacific Century Securities, LLC, and Revere Securities LLC, as well as more than 20 other issuers, underwriters, and individual principals of the underwriters. The complaint asserts claims under Sections 11 and 12(a)(2) of the Securities Act against the Company and other defendants, and claims under Section 15 of the Securities Act against certain individuals associated with the underwriter defendants. The proposed class includes persons who acquired the Company’s securities in, or pursuant or traceable to the offering documents for, its August 2025 initial public offering (the “IPO”) and allegedly suffered damages. The complaint alleges material misstatements and omissions in the offering documents concerning risks of stock-price manipulation and deficiencies in underwriter due diligence, anti-money laundering compliance, supervision, and business-communication monitoring. The complaint also makes general “blanket” allegations against the defendants relating to market manipulation.
The second action (“Action 2”) was filed on September 14, 2026 in the Supreme Court of the State of New York, New York County (Index No. 655238/2026), by Robert Lovett, on behalf of himself and other purported class plaintiffs against the Company, its former Chief Financial Officer, and directors, its independent auditor, and the IPO underwriters Dominari Securities LLC, Pacific Century Securities, LLC, and Revere Securities LLC. The complaint asserts claims under Sections 11 and 12(a)(2) of the Securities Act against all named defendants and Section 15 claims against the named individual defendants. The proposed class includes persons who acquired the Company’s securities in, or pursuant or traceable to the offering documents for, the IPO and allegedly suffered damages. The complaint alleges material misstatements and omissions in those documents concerning risks of stock-price manipulation and deficiencies in underwriter due diligence, anti-money laundering compliance, supervision, and business-communication monitoring.
The IPO offering documents referred to in both actions consisted of the Company’s registration statement on Form S-1, as amended, and related prospectuses under the Securities Act in connection with its August 2025 IPO. Both complaints seek unspecified compensatory damages, interest, costs and expenses, including attorneys’ and expert fees, rescission or rescissory damages, and equitable or other relief. Neither complaint asserts a fraud claim against the Company. Both actions are at a preliminary stage, and the Company intends to defend them vigorously. The Company’s deadline to respond to Action 1 has been extended to January 27, 2027, and the deadline to respond to Action 2 has been extended to December 11, 2026.
10. Subsequent Events
On
October 19, 2026, the Company filed a registration statement on Form S-8 registering the remaining
| 20 |
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
The following discussion and analysis should be read in conjunction with our financial statements and the related notes thereto. The management’s discussion and analysis contain forward-looking statements, such as statements of our plans, objectives, expectations, and intentions. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. These forward-looking statements are subject to risks and uncertainties, including those under “Risk Factors,” which appear in our annual report on Form 10-K filed with the SEC on March 30, 2026 that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. Our actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors. We do not undertake any obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this Quarterly Report.
Overview
We are a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and to improve patients’ lives by harnessing the power of natural substances. We are dedicated to discovering, developing and commercializing botanical medicines for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections. We are committed to “Bringing hope and healing through the wisdom of plants.”
Our business strategy is centered on developing innovative botanical drugs, with a focus on Phyto-N as our lead candidate, for the treatment of inflammatory diseases. Phyto-N is a proprietary botanical extract with chemical components and pharmacological activities that harnesses potential anti-inflammatory properties of a medicinal plant with a long history of human use. Phyto-N has approximately 30 years of human use experience and has shown positive results in animal models of multiple inflammatory diseases. We aim to prioritize the development of Phyto-N and its active compounds, to conduct further preclinical and clinical studies to evaluate its therapeutic potential and safety profile, and if warranted, to seek the necessary regulatory approval in order to commercialize Phyto-N.
On August 27, 2025, the Company completed its initial public offering (the “IPO”) and its shares of common stock are listed on The Nasdaq Capital Market (“Nasdaq”) under the symbol “CURX.” On September 12, 2025, we completed the additional closing related to the IPO, in which the underwriters in the IPO fully exercised their over-allotment option pursuant to the underwriting agreement dated August 25, 2025 with Dominari Securities, LLC, as representative of the underwriters. The Company is utilizing the net proceeds from the IPO primarily for (i) the development of its lead product candidate, Phyto-N, for the treatment of ulcerative colitis, atopic dermatitis, rheumatoid arthritis, gouty arthritis, and diabetic foot; (ii) the conduct of FDA-required GLP toxicology and pharmacokinetic studies and chemistry, manufacturing, and controls (“CMC”) activities for Phyto-N in ulcerative colitis and (iii) the preparation and submission of an investigational new drug (IND) application.
We are currently targeting submission of an IND for the treatment of ulcerative colitis in the fourth quarter of 2026. The timing of our IND submission will depend in part on the FDA’s response to our pre-IND meeting request, which we expect to receive by December 11, 2026, and on the completion of our ongoing IND-enabling studies, and the submission may occur in 2027. If allowed to proceed by the FDA, a Phase I trial may be initiated as early as 30 days after FDA receipt of the IND. If the Phase I trial is completed with positive results, we intend to proceed with a Phase II trial for ulcerative colitis as our lead indication. Contingent upon the success of our ulcerative colitis trials, available funding, and other strategic considerations, Curanex may subsequently initiate additional Phase II trials in other high-value indications such as atopic dermatitis, coronavirus (COVID-19), gout, diabetes, and NAFLD, or may seek to license out these indications to third parties at the Phase II stage. This multiple indication strategy represents our long-term vision to explore and maximize the value of Phyto-N and build a robust pipeline of botanical drug candidates targeting inflammatory diseases. The successful completion of these clinical trials could position Phyto-N as a potential botanical drug candidate for multiple inflammatory indications, addressing specific unmet medical needs. If approved, Phyto-N could provide patients with new treatment options for various inflammatory conditions.
The Company is also expanding its drug development pipeline and is focusing on a new core indication: cancer. The management believes that the focus on treatment of cancer aligns with the Company’s broader focus on treatment of serious diseases involving inflammation and metabolic disruption. While Curanex remains committed to advancing its lead ulcerative colitis program, the Company believes that by expanding its long-term pipeline potential by also focusing on cancer treatment, the Company will strengthen its positioning as an emerging therapeutics company.
GMP Pilot-Scale Manufacturing Milestone
In February 2026, Curanex successfully completed a pilot-scale batch of Phyto-N manufactured under Good Manufacturing Practice (GMP) standards. This GMP-compliant material is intended to support Good Laboratory Practice (GLP)-compliant toxicology, pharmacokinetic, and other IND-enabling nonclinical studies. Completion of the GMP pilot-scale batch represents an important step in strengthening the Company’s manufacturing foundation as it advances toward IND submission.
Key Chemistry, Manufacturing and Controls (CMC) activities completed to date include:
| ● | Development of quality control methods for botanical raw materials and extracted drug substance; | |
| ● | Laboratory scale process optimization, including extraction, concentration, and drying; and | |
| ● | Scale-up and production of GMP-compliant pilot material. |
With GMP pilot-scale material now available, the Company has initiated formal GLP toxicology and pharmacokinetic studies as part of its IND preparation.
Dose-Range Finding Toxicology Study
In March 2026, the Company announced the successful completion of a dose-range finding toxicology study of Phyto-N, conducted in Sprague-Dawley rats and dogs. The study evaluated repeat-dose oral tolerability over 28 days at multiple dose levels and was designed to inform dose selection and study design for the Company’s subsequent GLP-compliant toxicology studies. The maximum feasible dose identified in this study will serve as the high-dose anchor for the design of the pivotal GLP toxicology studies that will form a core component of the Company’s IND submission. These results support the Company’s target IND filing in the fourth quarter of 2026. The Company’s pivotal GLP repeat-dose toxicology studies of Phyto-N in rats and dogs are currently ongoing, and its GLP safety pharmacology studies evaluating cardiovascular, central nervous system (functional observational battery) and respiratory function are also underway. The Company submitted a pre-IND meeting request to the FDA on October 14, 2026. The Company expects to receive the FDA’s response by December 11, 2026. The Company intends to consider the FDA’s feedback before finalizing its IND submission.
| 21 |
Recent Developments
The Company Regained Compliance with the Minimum Bid Price Requirement
As previously reported by the Company on a Current Report on Form 8-K filed with the SEC on May 7, 2026, on May 5, 2026, the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq Staff”) notified the Company that while the Company did not regain compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq (the “Minimum Bid Price Requirement”) by May 4, 2026 (in accordance with the initial 180-day compliance period provided to the Company), Nasdaq granted the Company a second 180-day compliance period to regain compliance with the Minimum Bid Price Requirement by November 2, 2026. That determination to grant the Company an additional 180 calendar day period was based on the Company’s satisfaction of the continued listing requirements for the market value of publicly held shares and all other applicable requirements for initial listing on Nasdaq, with the exception of the Minimum Bid Price Requirement.
On September 3, 2026, Nasdaq confirmed that the Company had satisfied its minimum bid-price requirement following the effectiveness of the Reverse Stock Split and closed the matter.
On July 22, 2026, the Board approved the 1-for-20 Reverse Stock Split of the outstanding shares of the Company’s common stock, based on the prior approval and authorization by the holders of a majority of the outstanding voting power of the Company (the “Majority Stockholders”) to grant the Board the discretionary authority to determine the exact ratio of the reverse stock split within 1-for-10 and 1-for-50 reverse stock split range. The Reverse Stock Split became effective on August 20, 2026.
Upon the effectiveness of the Reverse Stock Split, every twenty shares of common stock outstanding immediately prior to the effectiveness were combined and reclassified into one share of common stock. No fractional shares were issued in connection with the Reverse Stock Split, and any fractional shares were rounded up to the next whole share. The number of authorized shares of common stock and the par value per share were not affected by the Reverse Stock Split.
2026 Equity Incentive Plan
On May 31, 2026, our Board of Directors adopted the 2026 Equity Incentive Plan (the “2026 Plan”), which became effective on June 11, 2026, upon approval by the Majority Stockholders. We adopted the 2026 Plan to enable us to attract, retain and incentivize qualified personnel as we advance our development programs toward our targeted IND submission, and to align the interests of our employees, directors and consultants with those of our stockholders. Pursuant to the 2026 Plan, the Company reserved an aggregate of 285,000 shares of our common stock for issuance as stock options, restricted stock, restricted stock units and other stock-based awards to our employees, directors and consultants. On July 21, 2026, we filed a first registration statement on Form S-8 registering in that registration statement 150,000 shares of common stock reserved under the 2026 Plan, representing approximately 10.58% of our issued and outstanding shares of common stock as of the date of filing. Between July 27 and August 7, 2026, the Company issued a total of 150,000 shares to six nonemployee consultants under the 2026 Plan, with an aggregate grant-date fair value of $573,100. On October 19, 2026, the Company filed a second registration statement on Form S-8, registering in that registration statement the remaining 135,000 shares under the 2026 Plan. As of the date of this Quarterly Report, the Company had not issued any shares of common stock pursuant to that second registration statement on Form S-8.
Results of Operations
Comparison of Results of Operations for the Three Months Ended September 30, 2026 and 2025
Revenue and Cost of Sales
We did not generate any revenue during the three months ended September 30, 2026, or 2025. This is consistent with our focus on advancing the development of our botanical drug candidates and progressing toward our clinical and regulatory milestones.
We anticipate generating revenue only upon successful commercialization of our product candidates or from entering into strategic licensing agreements. However, there is no assurance as to the timing or likelihood of these events.
| 22 |
Operating Expenses
General and Administrative Expenses
General and administrative expenses were $877,121 for the three months ended September 30, 2026, compared to $273,853 for the same period in 2025. The increase was primarily attributable to higher personnel-related expenses, including approximately $211,007 of increased payroll costs, reflecting recent hires and compensation for our founder and certain members of senior management following the completion of our IPO, whereas little or no cash compensation had been paid to these individuals prior to that time. The increase also reflects higher professional fees and other costs associated with operating as a public company. The current period also includes $34,491 of noncash consulting expense for strategic business-development and licensing services under the 2026 Plan.
Research and Development Expenses
Following our initial public offering, we continue to invest in research and development (“R&D”) activities primarily related to FDA-mandated investigational new drug (“IND”) studies targeting ulcerative colitis as our lead indication and cancer as our second core indication, as well as atopic dermatitis, rheumatoid arthritis, gouty arthritis, and diabetic foot. For the three months ended September 30, 2026, R&D expenses totaled $1,952,587, compared to $677,474 for the same period in 2025, primarily reflecting costs incurred under service agreements for IND-related studies and research activities, with such costs recognized over the respective service period in accordance with the terms of the underlying agreements. The current period includes $119,518 of noncash consulting expense for Australian clinical trial feasibility services. As of September 30, 2026, the Company recorded $314,783 in prepaid R&D, including $49,101 of advance payments to Contract Research Organizations (“CROs”) and Contract Development and Manufacturing Organizations (“CDMOs”) and other research service providers for services to be rendered under ongoing IND studies and $265,682 of noncash prepaid clinical-feasibility consulting services. We expect R&D spending to remain significant. Expense from existing prepaid study arrangements is expected to decline as the respective service periods conclude, while new spending is expected to increase in connection with our planned IND submission and subsequent clinical trial activities.
Other Income (Expense)
For the three months ended September 30, 2026, other income was $14,111, compared to $1,358 for the same period in 2025, primarily interest income earned on cash and cash equivalents. The increase was primarily attributable to higher interest income earned on the Company’s cash balances. The higher interest income primarily reflects increased cash balances following the receipt of net proceeds from the Company’s IPO. Interest expense was nil for the three months ended September 30, 2026, compared to $4,090 for the same period in 2025, following repayment of the shareholder loans in September 2025.
Net loss
As a result of the foregoing, the Company recorded a net loss of $2,815,597 for the three months ended September 30, 2026, compared to $954,059 for the three months ended September 30, 2025.
Comparison of Results of Operations for the Nine Months Ended September 30, 2026 and 2025
Revenue and Cost of Sales
We did not generate any revenue during the nine months ended September 30, 2026, or 2025. This is consistent with our focus on advancing the development of our botanical drug candidates and progressing toward our clinical and regulatory milestones.
We anticipate generating revenue only upon successful commercialization of our product candidates or from entering into strategic licensing agreements. However, there is no assurance as to the timing or likelihood of these events.
| 23 |
Operating Expenses
General and Administrative Expenses
General and administrative expenses were $2,536,161 for the nine months ended September 30, 2026, compared to $466,863 for the same period in 2025. The increase was primarily attributable to higher personnel-related expenses, including approximately $1,025,597 of increased payroll costs, reflecting recent hires and compensation for our founder and certain members of senior management following the completion of our IPO, whereas little or no cash compensation had been paid to these individuals prior to that time. The increase also reflects higher professional fees and other costs associated with operating as a public company. General and administrative expenses for the nine months ended September 30, 2026 also included $9,792 of non-cash stock-based compensation associated with the issuance of 1,200 shares of common stock in March 2026, compared to $nil in the prior year period. The current period also includes $34,491 of noncash consulting expense for strategic business-development and licensing services under the 2026 Plan.
Research and Development Expenses
Following our initial public offering, we continue to invest in research and development (“R&D”) activities primarily related to FDA-mandated investigational new drug (“IND”) studies targeting ulcerative colitis as our lead indication and cancer as our second core indication, as well as atopic dermatitis, rheumatoid arthritis, gouty arthritis, and diabetic foot. For the nine months ended September 30, 2026, R&D expenses totaled $6,802,466, compared to $679,574 for the same period in 2025, primarily reflecting costs incurred under service agreements for IND-related studies and research activities, with such costs recognized over the respective service period in accordance with the terms of the underlying agreements. The current period includes $119,518 of noncash consulting expense for Australian clinical trial feasibility services. As of September 30, 2026, the Company recorded $314,783 in prepaid R&D, including $49,101 of advance payments to Contract Research Organizations (“CROs”) and Contract Development and Manufacturing Organizations (“CDMOs”) and other research service providers for services to be rendered under ongoing IND studies and $265,682 of noncash prepaid clinical-feasibility consulting services. We expect R&D spending to remain significant. Expense from existing prepaid study arrangements is expected to decline as the respective service periods conclude, while new spending is expected to increase in connection with our planned IND submission and subsequent clinical trial activities.
Other Income (Expense)
For the nine months ended September 30, 2026, other income was $81,832, compared to $2,986 for the same period in 2025, primarily interest income earned on cash and cash equivalents. The increase was primarily attributable to higher interest income earned on the Company’s cash balances. The higher interest income primarily reflects increased cash balances following the receipt of net proceeds from the Company’s IPO. Interest expense was nil for the nine months ended September 30, 2026, compared to $8,537 for the same period in 2025, following repayment of the shareholder loans in September 2025.
Net loss
As a result of the foregoing, the Company recorded a net loss of $9,256,795 for the nine months ended September 30, 2026, compared to $1,151,988 for the nine months ended September 30, 2025.
Liquidity and Capital Resources
Since our inception through September 30, 2026, we have funded our operations principally through the issuance of equity and debt securities. We have not generated any revenue since inception and do not expect to generate revenue unless and until we successfully commercialize a product candidate or enter into strategic licensing arrangements.
On August 27, 2025, we closed our initial public offering pursuant to the Underwriting Agreement, receiving net cash proceeds of approximately $13.24 million after deducting underwriting discounts and commissions and offering expenses. On September 12, 2025, the underwriters exercised their over-allotment option in full, resulting in additional net proceeds of approximately $2.07 million. We have no committed sources of additional capital and no available credit facility.
| 24 |
As of September 30, 2026, we had cash and cash equivalents of $1,579,689, compared to $4,973,134 as of December 31, 2025, and an accumulated deficit of $14,104,350. We recorded a net loss of $9,256,795 for the nine months ended September 30, 2026, compared to $1,151,988 for the nine months ended September 30, 2025.
Our net cash used in operating activities for the nine months ended September 30, 2026 of $3,393,445 was substantially lower than our net loss for the period because a significant portion of our operating expenses was funded through the utilization of prepaid research and development balances paid in prior periods rather than through cash expenditures during the period. Our total prepaid expenses declined from $6,254,374 as of December 31, 2025 to $976,701 as of September 30, 2026, a reduction of $5,277,673 reflecting a $5,851,511 reduction in prepaid research and development, partially offset by increases in other prepaid balances. The ending prepaid balance includes $419,091 of noncash consulting-service prepayments recognized during the quarter. Noncash consulting expense of $154,009 also contributed to the difference between net loss and operating cash flows. The $5,696,764 prepaid movement in operating cash flows excludes the noncash addition to ending prepaids. As these prepaid balances are consumed, we expect our cash used in operating activities to increase substantially and to approximate our operating expenses.
We further expect our research and development expenditures to increase in connection with our targeted Investigational New Drug application submission, currently targeted for the fourth quarter of 2026 but which may occur in 2027, and the initiation of a Phase I clinical trial thereafter. Clinical trial activities require substantial capital that we have not yet secured.
Awards granted under the 2026 Plan will be settled in shares of our common stock and will not require the use of cash, which we expect will allow us to conserve cash resources in compensating our personnel as we advance our development programs. Any awards granted under the 2026 Plan will, however, dilute the ownership interests of our existing stockholders upon issuance. As of September 30, 2026, the Company had issued 150,000 shares under the 2026 Plan. These shares were issued to nonemployee consultants and recognized $154,009 of related expense, with $419,091 remaining prepaid at September 30, 2026. No cash proceeds were received from these issuances.
We will require additional capital to fund our operations. We may seek to raise additional capital through public or private equity offerings, debt financings, strategic collaborations or licensing arrangements. Our ability to raise capital on acceptable terms may be adversely affected by the trading price of our common stock, our ability to maintain compliance with Nasdaq listing requirements, and general market conditions. Additional equity financing would dilute our existing stockholders, and debt financing, if available, may involve restrictive covenants. If we are unable to raise additional capital when needed, we would be required to delay, reduce or eliminate certain of our development programs.
Going Concern Considerations
We have not generated any revenue since inception and have incurred recurring net losses and negative cash flows from operations. For the nine months ended September 30, 2026, we incurred a net loss of $9,256,795 and used cash in operating activities of $3,393,445. As of September 30, 2026, we had cash and cash equivalents of $1,579,689 and an accumulated deficit of $14,104,350.
As described above, our cash used in operating activities during the nine months ended September 30, 2026 was substantially lower than our operating expenses because a significant portion of those expenses was funded through prepaid balances paid in prior periods. As those balances are consumed, we expect our cash requirements to increase materially, and we expect our research and development expenditures to increase further in connection with our planned Investigational New Drug application submission and subsequent clinical trial activities.
Based on our current operating plan, we do not expect our existing cash and cash equivalents to be sufficient to fund our operations for at least twelve months from the date of issuance of the unaudited interim financial statements included in this Quarterly Report. These conditions raise substantial doubt about our ability to continue as a going concern.
| 25 |
Our plans to address these conditions include raising additional capital through the issuance of equity or debt securities, pursuing strategic collaborations or out-licensing arrangements for our product candidates, and reducing or deferring discretionary operating and development expenditures. We have no committed sources of additional capital, and there can be no assurance that we will be able to obtain additional financing on acceptable terms, or at all. Because these plans are not considered probable of being effectively implemented, they do not alleviate the substantial doubt about our ability to continue as a going concern.
If we are unable to obtain sufficient amount of additional capital, we may be required to reduce the scope of our planned development, If we are unable to raise additional capital when needed, we would be required to delay, reduce or eliminate certain of our development programs and could harm our business, financial condition and operating results. If we obtain additional funds by selling any of our equity, the percentage ownership of our stockholders will be reduced, stockholders may experience additional dilution, or the equity securities may have rights preferences or privileges senior to our common stock. If we issue debt securities, there may be negative covenants which may restrict our company’s activities. If adequate funds are not available to the Company when needed on satisfactory terms, we may be required to cease operating or otherwise modify our business strategy.
The unaudited interim financial statements included in this Quarterly Report have been prepared assuming we will continue as a going concern and do not include any adjustments to the carrying amounts or classification of assets and liabilities that might result from the outcome of this uncertainty. See Note 1 to our unaudited interim financial statements.
Contractual Obligations and Contingencies
On January 1, 2025, the Company assumed an office lease from Duraviva, a related party under common control, pursuant to a lease assignment agreement. The term of the lease extended to August 31, 2026. On August 13, 2026, the Company entered into a lease amendment extending the lease term to September 30, 2031, effective September 1, 2026. Additionally, during the 4th quarter of 2025, the Company entered into lease agreements for three motor vehicles with non-cancelable lease terms ranging from 36 to 51 months. These leases are classified as operating leases. In accordance with ASC 842, the Company recognized a right-of-use asset and corresponding lease liability as of the adoption date.
The lease liability was $542,090 as of September 30, 2026.
Off-Balance Sheet Arrangements
We did not have any off-balance sheet arrangements as of September 30, 2026.
Emerging Growth Company and Smaller Reporting Company Status
We continue to qualify as an emerging growth company (EGC) and smaller reporting company (SRC), enabling us to utilize scaled disclosures and defer adoption of certain accounting standards.
Item 3. Quantitative And Qualitative Disclosures About Market Risk.
We are a smaller reporting company, as defined by Rule 12b-2 of the Exchange Act, and are not required to provide the information required by this Item.
Item 4. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is accumulated and communicated to management, including our Principal Executive Officer and our Principal Financial Officer or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.
Our management, with the participation of our Principal Executive Officer and Principal Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2026. Based on that evaluation, our Principal Executive Officer and Principal Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report, these disclosure controls and procedures were not effective to provide reasonable assurance that information required to be disclosed in the reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management to allow timely decisions regarding required disclosure.
Our management does not expect that our disclosure controls and procedures will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected.
Changes in Internal Control over Financial Reporting
During the period covered by this Quarterly Report, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
| 26 |
PART II - OTHER INFORMATION
Item 1. Legal Proceedings
There are two (2) putative securities class actions, commenced in New York state court relating to the Company’s August 2025 IPO, described below:
The first action (“Action 1”) was filed on July 23, 2026 in the Supreme Court of the State of New York, New York County (Index No. 159271/2026), by Daymond Morales, et al. against the Company and its underwriters Dominari Securities LLC, Pacific Century Securities, LLC, and Revere Securities LLC, as well as more than 20 other issuers, underwriters, and individual principals of the underwriters. The complaint asserts claims under Sections 11 and 12(a)(2) of the Securities Act, against the Company and other defendants, and claims under Section 15 of the Securities Act against certain individuals associated with the underwriter defendants. The proposed class includes persons who acquired the Company’s securities in, or pursuant or traceable to the offering documents for, its August 2025 initial public offering (the “IPO”) and allegedly suffered damages. The complaint alleges material misstatements and omissions in the offering documents concerning risks of stock-price manipulation and deficiencies in underwriter due diligence, anti-money laundering compliance, supervision, and business-communication monitoring. The complaint also makes general “blanket” allegations against the defendants relating to market manipulation.
The second action (“Action 2”) was filed on September 14, 2026 in the Supreme Court of the State of New York, New York County (Index No. 655238/2026), by Robert Lovett, on behalf of himself and other purported class plaintiffs against the Company, its former Chief Financial Officer, and directors, its independent auditor, and the IPO underwriters Dominari Securities LLC, Pacific Century Securities, LLC, and Revere Securities LLC. The complaint asserts claims under Sections 11 and 12(a)(2) of the Securities Act against all named defendants and Section 15 claims against the named individual defendants. The proposed class includes persons who acquired the Company’s securities in, or pursuant or traceable to the offering documents for, the IPO and allegedly suffered damages. The complaint alleges material misstatements and omissions in those documents concerning risks of stock-price manipulation and deficiencies in underwriter due diligence, anti-money laundering compliance, supervision, and business-communication monitoring.
The IPO offering documents referred to in both actions consisted of the Company’s registration statement on Form S-1, as amended, and related prospectuses under the Securities Act in connection with its August 2025 IPO. Both complaints seek unspecified compensatory damages, interest, costs and expenses, including attorneys’ and expert fees, rescission or rescissory damages, and equitable or other relief. Neither complaint asserts a fraud claim against the Company. Both actions are at a preliminary stage, and the Company intends to defend them vigorously. The Company’s deadline to respond to Action 1 has been extended to January 27, 2027, and the deadline to respond to Action 2 has been extended to December 11, 2026.
Item 1A. Risk Factors.
We are a smaller reporting company, as defined by Rule 12b-2 of the Exchange Act, and are not required to provide the information under this item.
Item 2. Unregistered Sales Of Equity Securities And Use Of Proceeds
There were no sales of equity securities during the period covered by this Quarterly Report that were not registered under the Securities Act and were not previously reported in a Current Report on Form 8-K filed by the Company.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosure
Not applicable.
Item 5. Other Information
During
the three months ended September 30, 2026, none of the Company’s directors or officers
Item 6. Exhibits.
Exhibit Number |
Description | |
| 31.1* | Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act | |
| 31.2* | Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act | |
| 32.1* | Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | |
| 32.2* | Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | |
| 101.INS* | Inline XBRL Instance Document | |
| 101.SCH* | Inline XBRL Taxonomy Extension Schema Document | |
| 101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |
| 101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document | |
| 101.LAB* | Inline XBRL Taxonomy Extension Label Linkbase Document | |
| 101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |
| 104 | Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101) |
* Filed herewith
| 27 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Date: November 13, 2026 | CURANEX PHARMACEUTICALS INC | |
| By: | /s/ Jun Liu | |
| Name: | Jun Liu | |
| Title: | Chief Executive Officer and President | |
| (Principal Executive Officer) | ||
| Dated: November 13, 2026 | By: | /s/ Wanjun Zhang |
| Name: | Wanjun Zhang | |
| Title: | Chief Financial Officer | |
| (Principal Financial and Accounting Officer) | ||
| 28 |